Sunshine Biopharma Reports 2024 First Quarter Results: Revenues Up 54% [Yahoo! Finance]
Sunshine Biopharma Inc. (SBFM)
NASDAQ:AMEX Investor Relations:
sunshinebiopharma.com/press-releases.html
Company Research
Source: Yahoo! Finance
life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its 2024 first quarter report with the Securities and Exchange Commission. The Company reported gross revenues of $7,541,046 for the quarter ended March 31, 2024, a 54% increase over gross revenues of $4,894,053 for same period in 2023. The increase is due to new product launches and expanded marketing and sales efforts by the Company's wholly owned Canadian subsidiary, Nora Pharma Inc. The following are the Company's 2024 first quarter highlights: Sales in the first quarter grew to $7,541,046, compared to $4,894,053 during the same period last year, an increase of 54%. Net loss for the period ended March 31, 2024 was $(1,283,801) compared to a net loss of $(1,702,430) during the same period of 2023. On February 15, 2024, the Company completed an underwritten public offering for gross proceeds of approximately $10 million. The net proceeds received by the
Show less
Read more
Impact Snapshot
Event Time:
SBFM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SBFM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SBFM alerts
High impacting Sunshine Biopharma Inc. news events
Weekly update
A roundup of the hottest topics
SBFM
News
- Sunshine Biopharma Reports 2024 First Quarter Results: Revenues Up 54%Accesswire
- NORA PHARMA RECEIVES HEALTH CANADA APPROVAL FOR NIOPEG®, A BIOSIMILAR OF NEULASTA® [Yahoo! Finance]Yahoo! Finance
- NORA PHARMA RECEIVES HEALTH CANADA APPROVAL FOR NIOPEG®, A BIOSIMILAR OF NEULASTA®PR Web
- Predictive Oncology, BIMI Holdings, IMAC Holdings among healthcare movers [Seeking Alpha]Seeking Alpha
- Sunshine Biopharma's Nora Pharma Receives Health Canada Approval for Niopeg(R), a Biosimilar of Neulasta(R) [Yahoo! Finance]Yahoo! Finance
SBFM
Sec Filings
- 6/11/24 - Form 8-K
- 6/7/24 - Form 8-K
- 5/22/24 - Form 8-K
- SBFM's page on the SEC website